Anxiety and COPD Evaluation

The goal of the Anxiety and COPD Evaluation (ACE) study is to validate the AIR scale by
employing the Mini International Neuropsychiatric Interview to identify anxiety in 200
patients recruited at participating centers from the American Lung Association (ALA) Airways
Research Network.

Confidential, not

Inclusion Criteria:

- Post-bronchodilation FEV1 < 80% of the predictive normal value and FEV1 (forced
expiratory volume in one second) / Forced vital capacity(FVC) ratio < 0.7

- Clinically stable COPD as defined by stable maintenance of COPD medications and
absence of an exacerbation of symptoms requiring treatment with an antibiotic or
corticosteroids

Exclusion Criteria:

- Exacerbation of respiratory symptoms in the past six weeks that resulted in the need
for treatment or hospitalization

- Unstable coronary heart disease such as recent myocardial infarction (within 3
months), untreated arrhythmia, or unstable angina

- Major psychiatric disorders (except for depression and anxiety disorders) such as
schizophrenia, schizoaffective, or other disorders that in the opinion of the study
physician that would affect study participation

- Montreal Cognitive Assessment (MoCA) < 18

- Disease or condition expected to cause death within six months or inability to perform
study procedures, as judged by study physician